Abstract
The retinoblastoma gene, Rb, was originally identified as the tumor suppressor gene mutated in a rare childhood cancer called retinoblastoma (reviewed in [1]). Subsequent studies showed that Rb functions in a pathway that is often functionally inactivated in a large majority of human cancers. Interestingly, recent studies showed that in certain types of cancers, Rb function is actually required for cancer development. The intimate link between the Rb pathway and cancer development suggests that the status of Rb activity can potentially be used to develop targeted therapy. However, a prerequisite will be to understand the role of Rb and its interaction with other signaling pathways in cancer development. In this review, we will discuss the roles of Rb in proliferation, apoptosis and differentiation by reviewing the recent findings in both mammalian systems and different model organisms. In addition, we will discuss strategies that can be employed that specifically target cancer cells based on the status of the Rb pathway.
Current Drug Targets
Title: The Rb Pathway and Cancer Therapeutics
Volume: 10 Issue: 7
Author(s): W. Du and J. S. Searle
Affiliation:
Abstract: The retinoblastoma gene, Rb, was originally identified as the tumor suppressor gene mutated in a rare childhood cancer called retinoblastoma (reviewed in [1]). Subsequent studies showed that Rb functions in a pathway that is often functionally inactivated in a large majority of human cancers. Interestingly, recent studies showed that in certain types of cancers, Rb function is actually required for cancer development. The intimate link between the Rb pathway and cancer development suggests that the status of Rb activity can potentially be used to develop targeted therapy. However, a prerequisite will be to understand the role of Rb and its interaction with other signaling pathways in cancer development. In this review, we will discuss the roles of Rb in proliferation, apoptosis and differentiation by reviewing the recent findings in both mammalian systems and different model organisms. In addition, we will discuss strategies that can be employed that specifically target cancer cells based on the status of the Rb pathway.
Export Options
About this article
Cite this article as:
Du W. and Searle S. J., The Rb Pathway and Cancer Therapeutics, Current Drug Targets 2009; 10 (7) . https://dx.doi.org/10.2174/138945009788680392
DOI https://dx.doi.org/10.2174/138945009788680392 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews A Narrative Review of Recent Studies on the Role of Vitamin D in the Prevention of Cardiac and Renal Risk and Additional Considerations for COVID-19 Vulnerability
Current Vascular Pharmacology A Classification Method for Microarrays Based on Diversity
Current Bioinformatics Serum Interleukin-33 as a Biomarker in Predicting Neonatal Sepsis in Premature Infants
Combinatorial Chemistry & High Throughput Screening ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Early-Life Immune Insult and Developmental Immunotoxicity (DIT)-Associated Diseases: Potential of Herbal- and Fungal-Derived Medicinals
Current Medicinal Chemistry Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Turner Syndrome : How Is It Made Up?
Current Genomics Editorial (Hot Topic: Survival Signaling Through Focal Adhesion Kinase in Tumors)
Anti-Cancer Agents in Medicinal Chemistry Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: Thyroid Cancer in Children and Adolescents)
Current Pediatric Reviews Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets Occupational Exposure and Occupational Asthma: Difference in Practices in Developed Countries v/s Developing Countries
Current Respiratory Medicine Reviews Reproductive Effects of Low-to-Moderate Medical Radiation Exposure
Current Medicinal Chemistry Methotrexate Induced Pneumonitis: A Review Article
Current Respiratory Medicine Reviews Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Impacts of Amine Functionalized Iron Oxide Nanoparticles on HepG2 Cell Line
Current Nanoscience In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets The Expanding Universe of γ δ T Lymphocytes: Subsets, Generation and Function
Current Immunology Reviews (Discontinued) A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design